Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127808 | 0.90 | RXRA (0.38) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL31642671 | 0.90 | RXRA (0.38) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL30542408 | 0.88 | RXRA (0.37) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL25373201 | 0.88 | RXRA (0.37) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL25373206 | 0.88 | RXRA (0.37) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL25795334 | 0.86 | CYP4F2 (0.41) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL29344298 | 0.86 | CYP4F2 (0.41) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL29804208 | 0.85 | RXRA (0.41) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL21196028 | 0.85 | RXRA (0.41) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL30922527 | 0.85 | RXRA (0.39) | ALDH1A1LMNAPOLBRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2025136346-A1 | INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024233776-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024103010-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | ALDH1A1 3402/4885LMNA 2197/4885POLB 1239/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | ALDH1A1 3351/4885LMNA 3544/4885POLB 3739/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | ALDH1A1 3402/4885LMNA 2197/4885POLB 1239/4885 |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | ALDH1A1 3402/4885LMNA 2197/4885POLB 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.